BioCentury
ARTICLE | Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

January 29, 2019 12:02 PM UTC

OncoCyte Corp. (NYSE-A:OCX) said Tuesday its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. The news sent the company’s shares soaring $4.09 (225%) to $5.91.

BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX), which holds about 36% of OncoCyte shares, was also up on Tuesday, gaining $0.50 (55%) to $1.39 on NYSE-A and adding NIS104.10 (32%) to NIS428.80 in Tel Aviv...

BCIQ Company Profiles

OncoCyte Corp.